Company StemRIM

4599

JP3399690001

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for StemRIM

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 10/05/2024 am IST			5-day change	1st Jan Change
470 ^JPY	0.00%		-1.05%	-18.69%

09/05	StemRIM to Seek Shareholders' Approval on Capital Stock Reduction	MT
13/03	StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy	CI

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Companyâs main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

Number of employees: 45

JPY in Million	2022	Weight	2023	Weight	Delta
Regenerative Medicine 100.0 %	23	100.0 %	2,350	100.0 %	+10,128.06%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	23	100.0 %	2,350	100.0 %	+10,128.06%

Managers	Title	Age	Since
Masatsune Okajima CEO	Chief Executive Officer	56	01/19/01
Kensuke Tomita CHM	Chairman	75	01/13/01
Tomoyuki Hoshino ADM	Chief Administrative Officer	-	-
Takahiko Yamazaki CTO	Chief Tech/Sci/R&D Officer	53	01/07/01
Koichi Yokota CTO	Chief Tech/Sci/R&D Officer	66	01/13/01
Tsutomu Kanesaki PRN	Corporate Officer/Principal	51	01/10/01

Members of the board	Title	Age	Since
Masatsune Okajima CEO	Chief Executive Officer	56	01/19/01
Kensuke Tomita CHM	Chairman	75	01/13/01
Koichi Yokota CTO	Chief Tech/Sci/R&D Officer	66	01/13/01
Noriko Sawai BRD	Director/Board Member	52	01/19/01
Tsutomu Kanesaki PRN	Corporate Officer/Principal	51	01/10/01
Takahiko Yamazaki CTO	Chief Tech/Sci/R&D Officer	53	01/07/01
Hirotada Nagai BRD	Director/Board Member	47	14/20/14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	61,499,200	25,581,279 ( 41.60 %)	121 ( 0.000197 %)	41.60 %

Name	Equities	%	Valuation
Katsuto Tamai 15.78 %	9,702,000	15.78 %	31 M ¥
Keiko Tamai 8.785 %	5,400,000	8.785 %	17 M ¥
Kensuke Tomita 8.158 %	5,015,000	8.158 %	16 M ¥
Daisuke Gomi 4.636 %	2,850,000	4.636 %	9 M ¥
Takahiko Yamazaki 3.986 %	2,450,000	3.986 %	8 M ¥
Miyako Capital KK 3.161 %	1,943,000	3.161 %	6 M ¥
Tsutomu Kanesaki 3.000 %	1,844,000	3.000 %	6 M ¥
SHIONOGI & CO., LTD. 2.928 %	1,800,000	2.928 %	6 M ¥
Toshiyuki Ohkubo 1.492 %	917,000	1.492 %	3 M ¥
ECS YK 1.166 %	717,000	1.166 %	2 M ¥

StemRIM, Inc.

Saito Bio Incubator, 3/F 7-7-15 Saito-Asagi

567-0085, Osaka

http://www.stemrim.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
STEMRIM	-18.69%	186M
CSL LIMITED	-2.61%	88.47B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.71B
BIOGEN INC.	-14.40%	32.43B
UCB	+55.89%	24.28B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.52B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	12.17B
INCYTE CORPORATION	-15.50%	12.01B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	12B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	8.87B

Biopharmaceuticals